Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Everolimus in Recurrent High-Grade Glioma
NCT03834740Phase 1Completed
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Jan 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ribociclib in glioma (3 cohorts), sponsored by St. Joseph's Hospital and Medical Center. Primary endpoints: Maximum Tolerated Dose up to 24 months, Total and Unbound Ribociclib Concentration and 3 more. Started Jan 2019; status: completed.
02
Drugs
ribociclib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03834740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834740.